To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be randomly allocated to receive 2 protexin capsules or placebos for 7 months; both groups will be advised to adherence our diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis will be assessed and compared between groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
54
2 symbiotics capsules per day for 28 weeks
2 Maltodexterin capsules as a placebo per day for 28 weeks
Alaninaminotransferase (ALT)
Time frame: 28 weeks
Liver fibrosis
Time frame: 28 weeks
Body Mass Index (BMI)
Time frame: 28 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.